Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib)

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3593-3600

  Aristegui J ^a   Dal Re R ^b   Diez Delgado J ^c   Mares J ^d   Casanovas, J M ^e   Garcia Corbeira P ^b   De Frutos, E ^f   Van Esso, D ^g   Verdaguer, J ^h   De La Flor, J ⁱ   Moraga, F ^j   Boceta, R ^b   Garcia Martinez J A ^b  

^a HOSPITAL DE BASURTO   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c HOSPITAL TORRECÁRDENAS   (Spain)

^d Mares Riera Paediatric Institute   (Spain)

^e CAP Roquetes   (Spain)

^f ABS Canovellas   (Spain)

^g ABS Serraparera   (Spain)

^h Hospital Sant Llàtzer   (Spain)

ⁱ CAP Sant Vicenç Dels Horts   (Spain)

^j HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS POLIOMYELITIS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; HEXAVALENT VACCINE; INACTIVATED VACCINE; MENINGOCOCCUS VACCINE; PENTAVALENT VACCINE; POLIO TYPE 2 ANTIBODY; POLIO TYPE 2 ANTIGEN; UNCLASSIFIED DRUG; VIRUS VACCINE;

AGE; ANOREXIA; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIPHTHERIA; DROWSINESS; DRUG CONJUGATION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFECTION CONTROL; INJECTION; IRRITABILITY; LICENSING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORMAL HUMAN; PAIN; PATIENT; PHASE 3 CLINICAL TRIAL; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; RECORDING; RECTUM TEMPERATURE; SYMPTOM; TETANUS; THIGH; VACCINATION; VIRUS TITRATION;

EID: 3142736005     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00420-1     Document Type: Article

References (29)

1. Edwards K.M., Decker M.D. Challenges for licensure of new diphtheria, tetanus toxoid, acellular pertussis (DTPa) combination vaccines: counterpoint. Pediatr Infect Dis J. 15:1996;1070-1073.
2. American Academy of Pediatrics. Committee on Infectious Diseases: recommended childood immunization schedule-United Sates. Pediatrics 2000;105:148-51.
3. Decker M.D., Edwards K.M. Combination vaccines: problems and promise. J Pediatr. 137:2000;291-295. [editorial].
4. Salisbury DM, Dittmann S. Immunization in Europe. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia, PA: Saunders; 1999. p. 1033-46.
5. American Academy of Pediatrics. Committee on Infectious Diseases: prevention of poliomyelitis: recommendations for the use of only inactivated poliovirus vaccine for routine immunization. Pediatrics 1999;104:1404-6.
6. Meyer CU, Bilen G, Urschel S, Schuind A, Slauoi M, Clemens R, et al. Integration of IPV into multivalent DTPa-HBV-combination vaccines suggests promotion of pertussis-related T-cellular immune responses. Abstract 698 Presented at the 36th Annual Meeting of the Infectious Diseases Society of America (IDSA). Denver, Colorado; 12-15 November 1998.
7. Schmitt H.J., Von Kries R., Hassenpflug B., Hermann M., Siedler A., Niessing W.et al. Haemophilus influenzae type b disease: impact and effectiveness of diphteria-tetanus toxoids-acellular pertussis (inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J. 20:2001;767-774.
8. Camargo M.E., Silveira L., Furuta J.A., Oliveira E.P.T., Germak O.A. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol. 20:1984;772-774.
9. Melville-Smith M.E., Seagroatt V.A., Watkins J.T. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralisation test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 11:1983;137-144.
10. Karpinski K.F., Hayward S., Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods. 103:1987;189-194.
11. World Health Organization. Progress in the control of viral hepatitis: memorandum for a WHO meeting, Bull WHO 1988;66:443-5.
12. Käythy H., Peltola K., Mäkelä P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 147:1983;1100.
13. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 149:1983;1034-1035.
14. Standard procedure for determining immunogenicity to poliovirus using microneutralization test (WHO/EPI/GEN 93.9).
15. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
16. Zepp F, Schuind A, Habermehl P, Huff J, Jahn K, Thoelen S. Evolution of combination vaccines: comparison of two candidate vaccines with licensed vaccines. Abstract P30 Presented at 18th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Noordwijk, The Netherlands; 3-5 May 2000.
17. Jahn K, Huff J, Schund A, Kowalzik F, Faber J, Habermehl P, et al. Multi-center primary vaccination trial to assess the safety of a hexavalent DTPa-HBV-IPV/Hib vaccine in infants. Abstract 58 Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada; 17-20 September 2000.
18. Schmitt H.J., Knuf M., Ortiz E., Sanger R., Uwamwezi M.C., Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr. 137:2000;304-312.
19. Cohen R, Schuerman L. Reactogenicity of a new DTPa-HBV-IPV (+ &/Hib) vaccines after primary and booster doses. Abstract P31 Presented at 18th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Noordwijk, The Netherlands; 3-5 May 2000.
20. Blatter M, Pichichero M, Harrison C, Johnson C, Steinhoff M, Senders S, et al. A combination DTPa-HepB-IPV/Hib vaccine administered to infants at 2, 4 and 6 months of age with or without a hepatitis B vaccine birth dose. Abstract 626 Presented at the 38th Annual Meeting of the Infectious Diseases Society of America (IDSA). New Orleans, Louisiana; 7-10 September 2000.
21. Blatter MM, Reisinger KS, Terwelp DR, DelBuono FJ, Howe BJ. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis (DT-tricomponent Pa)-hepatitis B (HB)-inactivated polioviru (IPV) admixed with Haemophilus influenzae type b (Hib) vaccine in infants. Abstract 813 Presented at The American Pediatric Society and The Society for Pediatric Research Meeting. New Orleans, Louisiana; 1-5 May 1998. Pediatr Res 1998;43:141A.
22. Decker M.D., Edwards K.M., Bradley R., Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr. 120:1992;184-189.
23. Zepp F., Scmitt H.J., Kaufhold A., Scuind A., Knuf M., Habermehl P.et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b PRP (Hib) boosters in children primed with tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr. 156:1997;18-24.
24. Schmitt H.J., Zepp F., Muschenborn S., Sumenicht C., Schuind A., Beutel K.et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr. 157:1998;208-214.
25. Zepp F, Meyer CU, Kowalzol P, Habermehl P, Stahmer S, Ortiz E, et al. Evaluation of the immunological memory induced by primary vaccination with Haemophilus influenzae type b tetanus conjugate vaccine co-administered with various DTPa-based vaccines. Abstract 242 Presented at the 439th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, California; 26-29 September 1999.
26. Eskola J., Ward J., Dagan R., Goldblatt D., Zepp F., Siegrist C.A. Combined vaccination of Haemophilus influenzae type b conjugate and diphteria-tetanus-pertussis containing acellular pertussis. Lancet. 354:1999;2063-2068.
27. Schmitt HJ, Knuf M, Beutel K, Schuerman L. Antibody persistence, PRP specific immune memory and booster responses in children primed with a new combination vaccine DTPa-HBV-IPV given as either a mixed or separate injection. Abstract P29 Presented at 18th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Noordwijk, The Netherlands; 3-5 May 2000.
28. Heininger U, Schuerman L. Evidence for pre-booster antibody persistence in an open randomized study on infants primed with DTPa-HBV-IPV/Hib or DTPa-IPV/Hib + HBV vaccines at 3-5 months of age. Abstract Presented at 19th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Istambul, Turkey; 26-28 March 2001.
29. Comité Asesor de Vacunas de la AEP. Calendario vacunal de la Asociación Española de Pediatría 2001-2002. An Esp Pediatr 2001;55:30-8.